Editor's Choice

Rosiglitazone: a cautionary tale

BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c4896 (Published 07 September 2010) Cite this as: BMJ 2010;341:c4896

This article has a correction. Please see:

  1. Fiona Godlee, editor, BMJ
  1. fgodlee{at}bmj.com

    This week a BMJ investigation suggests that the diabetes drug rosiglitazone should never have been licensed and should now be withdrawn (doi:10.1136/bmj.c4848).

    The tale of rosiglitazone is a cautionary one from which we must hope the main parties will learn for the future. Hailed as a much needed new approach for patients with type 2 diabetes, the drug was licensed 10 years ago with only limited evidence of its effectiveness and concerns over its safety. While allowing the drug onto the market, the regulators asked the manufacturer GlaxoSmithKline to do additional trials. This the company did while marketing the drug around the …

    View Full Text

    Sign in

    Log in through your institution